Abstract:Background: Tumor-associated macrophages (TAMs) and dysregulated tumor epigenetics contribute to hepatocellular carcinoma (HCC) progression. However, the mechanistic interactions between TAMs and tumor epigenetics remain poorly understood. Methods: Immunohistochemistry and multiplexed fluorescence staining were performed to evaluate the correlation between TAMs numbers and UHRF1 expression in human HCC tissues. PGE2 neutralizing antibody and COX-2 inhibitor were used to analyze the regulation of TAMs isolated from HCC tissues on UHRF1 expression. Multiple microRNA prediction programs were employed to identify microRNAs that target UHRF1 3'UTR. Luciferase reporter assay was applied to evaluate the regulation of miR-520d on UHRF1 expression. Chromatin immunoprecipitation (ChIP) assays were performed to assess the abundance of H3K9me2 in the KLF6 promoter and DNMT1 in the CSF1 promoter regulated by UHRF1. The functional roles of TAM-mediated oncogenic network in HCC progression were verified by in vitro colony formation assays, in vivo xenograft experiments and analysis of clinical samples. Results: Here, we find that TAMs induce and maintain high levels of HCC UHRF1, an oncogenic epigenetic regulator. Mechanistically, TAM-derived PGE2 stimulates UHRF1 expression by repressing miR-520d that targets the 3'-UTR of UHRF1 mRNA. In consequence, upregulated UHRF1 methylates H3K9 to diminish tumor KLF6 expression, a tumor inhibitory transcriptional factor that directly transcribes miR-520d. PGE2 reduces KLF6 occupancy in the promoter of miR-520d, dampens miR-520d expression, and sustains robust UHRF1 expression. Moreover, UHRF1 promotes CSF1 expression by inducing DNA hypomethylation of the CSF1 promoter and supports TAM accumulation. Conclusions: Capitalizing on studies on HCC cells and tissues, animal models, and clinical information, we reveal a previously unappreciated TAM-mediated oncogenic network via multiple reciprocal enforcing molecular nodes. Targeting this network may be an approach to treat HCC patients.

Estrogen Represses Hepatocellular Carcinoma (HCC) Growth Via Inhibiting Alternative Activation of Tumor-associated Macrophages (Tams)*

Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome

Role of estrogen in hepatocellular carcinoma: is inflammation the key?

Effects of Estrogen and Estrogen Receptors on Transcriptomes of HepG2 Cells: A Preliminary Study Using RNA Sequencing

Oestrogen Attenuates Tumour Progression in Hepatocellular Carcinoma

Therapeutic Value of Estrogen Receptor α in Hepatocellular Carcinoma Based on Molecular Mechanisms

A Multi-Omics Study Revealing the Metabolic Effects of Estrogen in Liver Cancer Cells HepG2

TR4 Nuclear Receptor Suppresses HCC Cell Invasion Via Downregulating the EphA2 Expression

Data from Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib Plus NK Cells Immunotherapy to Better Suppress HCC Progression

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

Estrogen Receptor 1 Signaling in Hepatic Stellate Cells Designates Resistance to Liver Fibrosis

Estrogen induces LCAT to maintain cholesterol homeostasis and suppress hepatocellular carcinoma development

GPER1 signaling restricts macrophage proliferation and accumulation in human hepatocellular carcinoma

Crosstalk between macrophage-derived PGE 2 and tumor UHRF1 drives hepatocellular carcinoma progression

ECT2 Overexpression Promotes the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma Via the ECT2/PLK1/PTEN Pathway.

Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors

Tumor-Linked Macrophages Promote HCC Development by Mediating the CCAT1/Let-7b/HMGA2 Signaling Pathway

Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B

Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.

Protein Tyrosine Phosphatase Receptor S Acts As a Metastatic Suppressor in Hepatocellular Carcinoma by Control of Epithermal Growth Factor Receptor-Induced Epithelial-Mesenchymal Transition.

Inhibition of MTA1 by ERα Contributes to Protection Hepatocellular Carcinoma from Tumor Proliferation and Metastasis